By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Where Your Profits Grow Sky High.

COVID-19 vaccine from Tyrol

person in protective suit with vaccine © CureVac

Preparations for the start of production, technology transfer and testing have already begun. Novartis intends to manufacture the mRNA and the pre-formulated active substances for up to 50 million doses by the end of 2021 and for up to 200 million doses in 2022. The beginning of deliveries will likely take place as of the summer of 2021. Production will occur in an innovative, high-tech manufacturing plant which is already under construction and which will be adapted to the needs of vaccine production for CureVac.

About CureVac

CureVac is a global biopharmaceutical company in the field of mRNA technology with more than 20 years of experience in the development and optimisation of this versatile molecule for medical purposes. The company is headquartered in Tübingen, Germany, and employs a workforce of more than 600 employees at its sites in Tübingen, Frankfurt and Boston, USA.

About Novartis

Kundl is a central development and production site of the Novartis Group and headquarters of Sandoz GmbH with a focus on generic drug manufacturing. The plant in Kundl specialises in biotechnologically produced drugs, from research and development to production. The emphasis is on the production of active pharmaceutical ingredients for antibiotics and antibiotic finished dosage forms. The factory in Kundl was already established in the year 1946.

Continue reading and learn more about the life sciences sector in Austria!

Read more:

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin



Meet us at events, seminars and trade shows - worldwide.

  • Austria – Carinthia your ICT Hub in the Heart of Europe

    14.04.2021/ 02.30 pm (India Time) , Online Conference

Austria Map

Find the perfect location for your company

A country like Austria considered to be an especially good terrain for upscale industrial segments, and with a particular emphasis on research and environmental friendliness, represents a major opportunity for SIAD. Our corporate goal is namely to assist the customer and provide support in improving the productivity and the environmental compatibility of its work processes.


More testimonials

news from the business location Austria

Austrians conduct research in New York on low-priced vaccine

Two Austrians are conducting research in New York on a vaccine against the coronavirus which is designed to be available at a particularly low price and also be easy to dispense.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts